Le Lézard
Classified in: Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

Cognex Reports Record Quarterly Revenue


Cognex Corporation (NASDAQ: CGNX) today reported financial results for the third quarter of 2021 which included record quarterly revenue. Table 1 below shows selected financial data for Q3-21 compared with Q3-20 and Q2-21, and for the nine months of 2021 compared with the same period in 2020.

Table 1
(Dollars in thousands, except per share amounts)

 

 

 

 

 

Revenue

 

 

 

Net Income

 

Net Income

per Diluted

Share

Non-GAAP

Net Income

per Diluted
Share*

Quarterly Comparisons

 

 

 

 

Current quarter: Q3-21

$284,848

$78,900

$0.44

$0.40

Prior year's quarter: Q3-20

$251,073

$87,506

$0.49

$0.47

Change: Q3-20 to Q3-21

13%

(10)%

(10)%

(15)%

Prior quarter: Q2-21

$269,158

$77,598

$0.43

$0.43

Change: Q2-21 to Q3-21

6%

2%

2%

(7)%

Year-to-Date Comparisons

 

 

 

 

Nine months ended Oct. 3, 2021

$793,033

$226,346

$1.26

$1.20

Nine months ended Sept. 27, 2020

$587,405

$106,841

$0.61

$0.77

Change from first nine months of 2020 to first nine months of 2021

35%

112%

107%

56%

*Non-GAAP net income per diluted share excludes restructuring and other charges that occurred predominantly in Q2-20, and discrete tax adjustments. A reconciliation from GAAP to Non-GAAP is shown in Exhibit 2 of this news release.

"We are pleased to report the highest quarterly revenue in our company's 40-year history, surpassing the prior record set last quarter," said Robert J. Willett, Chief Executive Officer of Cognex. "We were also highly profitable and reported an operating margin of 31%, which is above our 30% long-term target. And we were able to accomplish these achievements while operating in a very challenging supply environment."

Mr. Willett continued, "In regard to supply, we believe we have been managing global chip shortages relatively well so far. However, the constraints are beginning to hold back revenue growth and drive cost increases more noticeably. Demand from customers is high and meeting their needs remains our top priority as we work through this situation."

Details of the Quarter

Statement of Operations Highlights ? Third Quarter of 2021

Balance Sheet Highlights ? October 3, 2021

Financial Outlook ? Q4 2021

Non-GAAP Financial Measures

Analyst Conference Call and Simultaneous Webcast

About Cognex Corporation

Cognex Corporation designs, develops, manufactures, and markets a wide range of image-based products, all of which use artificial intelligence (AI) techniques that give them the human-like ability to make decisions on what they see. Cognex products include machine vision systems, machine vision sensors, and barcode readers that are used in factories and distribution centers around the world where they eliminate production and shipping errors.

Cognex is the world's leader in the machine vision industry, having shipped more than 3 million image-based products, representing over $8 billion in cumulative revenue, since the company's founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.

Certain statements made in this news release, which do not relate solely to historical matters, are forward-looking statements. These statements can be identified by use of the words "expects," "anticipates," "estimates," "believes," "projects," "intends," "plans," "will," "may," "shall," "could," "should," and similar words and other statements of a similar sense. These statements are based on our current estimates and expectations as to prospective events and circumstances, which may or may not be in our control and as to which there can be no firm assurances given. These forward-looking statements, which include statements regarding business and market trends, future financial performance, the expected impact of the COVID-19 pandemic on our assets, business and results of operations, customer demand and order rates and timing of related revenue, managing supply shortages, future product mix, restructuring and other cost-savings initiatives, research and development activities, sales and marketing activities, new product offerings, capital expenditures, investments, liquidity, dividends and stock repurchases, strategic and growth plans, and estimated tax benefits and expenses and other tax matters, involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include: (1) the impact, duration, and severity of the COVID-19 pandemic; (2) potential disruptions to our business due to restructuring activities; (3) the loss of, or curtailment of purchases by, large customers in the consumer electronics and logistics industries; (4) the reliance on revenue from the automotive industry; (5) the reliance on key suppliers to manufacture and deliver critical components for our products; (6) disruptions in the supply chain, which could impact timely delivery of customer orders, cause customer orders to decrease, or increase costs to fulfill orders, including costs for components or freight; (7) the failure to effectively manage product transitions or accurately forecast customer demand; (8) the inability to design and manufacture high-quality products; (9) the inability to attract and retain skilled employees and maintain our unique corporate culture; (10) the failure to effectively manage our growth; (11) the inability to achieve growth in revenue and profits from the logistics industry; (12) the technological obsolescence of current products and the inability to develop new products; (13) the failure to properly manage the distribution of products and services; (14) the impact of competitive pressures; (15) the challenges in integrating and achieving expected results from acquired businesses; (16) potential disruptions in our business systems; (17) information security breaches and cyber-attacks; (18) the inability to protect our proprietary technology and intellectual property; (19) potential impairment charges with respect to our investments or acquired intangible assets; (20) exposure to additional tax liabilities; (21) fluctuations in foreign currency exchange rates and the use of derivative instruments; (22) our involvement in time-consuming and costly litigation; (23) unfavorable global economic conditions; and (24) economic, political, and other risks associated with international sales and operations; and the other risks detailed in Cognex reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2020 and Form 10-Q for the fiscal quarter ended October 3, 2021. You should not place undue reliance upon any such forward-looking statements, which speak only as of the date made. Cognex disclaims any obligation to update forward-looking statements after the date of such statements.

Exhibit 1

COGNEX CORPORATION
Statements of Operations
(Unaudited)
Dollars in thousands, except per share amounts

 

 

Three-months Ended

 

Nine-months Ended

 

Oct. 3,
2021

 

Jul. 4,
2021

 

Sept. 27,
2020

 

Oct. 3,
2021

 

Sept. 27,
2020

Revenue

$

284,848

 

 

$

269,158

 

 

$

251,073

 

 

$

793,033

 

 

$

587,405

 

Cost of revenue (1)

85,712

 

 

68,432

 

 

59,741

 

 

208,189

 

 

151,261

 

Gross margin

199,136

 

 

200,726

 

 

191,332

 

 

584,844

 

 

436,144

 

Percentage of revenue

70

%

 

75

%

 

76

%

 

74

%

 

74

%

Research, development, and engineering expenses (1)

34,476

 

 

31,302

 

 

30,240

 

 

99,883

 

 

96,583

 

Percentage of revenue

12

%

 

12

%

 

12

%

 

13

%

 

16

%

Selling, general, and administrative expenses (1)

77,113

 

 

76,843

 

 

64,206

 

 

226,380

 

 

193,497

 

Percentage of revenue

27

%

 

29

%

 

26

%

 

29

%

 

33

%

Restructuring charges

?

 

 

?

 

 

251

 

 

?

 

 

15,049

 

Intangible asset impairment charges

?

 

 

?

 

 

?

 

 

?

 

 

19,571

 

Operating income

87,547

 

 

92,581

 

 

96,635

 

 

258,581

 

 

111,444

 

Percentage of revenue

31

%

 

34

%

 

38

%

 

33

%

 

19

%

Foreign currency gain (loss)

(586)

 

 

(639)

 

 

2,357

 

 

(2,233)

 

 

(310)

 

Investment and other income

1,623

 

 

1,596

 

 

2,317

 

 

4,605

 

 

10,857

 

Income before income tax expense

88,584

 

 

93,538

 

 

101,309

 

 

260,953

 

 

121,991

 

Income tax expense

9,684

 

 

15,940

 

 

13,803

 

 

34,607

 

 

15,150

 

Net income

$

78,900

 

 

$

77,598

 

 

$

87,506

 

 

$

226,346

 

 

$

106,841

 

Percentage of revenue

28

%

 

29

%

 

35

%

 

29

%

 

18

%

 

 

 

 

 

 

 

 

 

 

Net income per weighted-average common and common-equivalent share:

 

 

 

 

 

 

 

 

 

Basic

$

0.45

 

 

$

0.44

 

 

$

0.50

 

 

$

1.28

 

 

$

0.62

 

Diluted

$

0.44

 

 

$

0.43

 

 

$

0.49

 

 

$

1.26

 

 

$

0.61

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common and common-equivalent shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

176,812

 

 

176,626

 

 

173,943

 

 

176,572

 

 

172,881

 

Diluted

180,342

 

 

179,991

 

 

177,138

 

 

180,109

 

 

176,038

 

 

 

 

 

 

 

 

 

 

 

Cash dividends per common share

$

0.060

 

 

$

0.060

 

 

$

0.055

 

 

$

0.180

 

 

$

0.165

 

Cash and investments per common share

$

5.57

 

 

$

5.39

 

 

$

5.80

 

 

$

5.57

 

 

$

5.80

 

Book value per common share

$

8.44

 

 

$

8.09

 

 

$

8.62

 

 

$

8.44

 

 

$

8.62

 

 

 

 

 

 

 

 

 

 

 

(1) Amounts include stock-based compensation expense, as follows:

 

 

 

 

 

 

 

 

 

Cost of revenue

$

366

 

 

$

351

 

 

$

324

 

 

$

965

 

 

$

1,041

 

Research, development, and engineering

3,091

 

 

3,064

 

 

2,815

 

 

10,158

 

 

10,582

 

Selling, general, and administrative

7,157

 

 

7,315

 

 

6,129

 

 

22,230

 

 

20,453

 

Total stock-based compensation expense

$

10,614

 

 

$

10,730

 

 

$

9,268

 

 

$

33,353

 

 

$

32,076

 

 

 

 

 

 

 

 

 

 

 

Exhibit 2

 

COGNEX CORPORATION
Reconciliation of Selected Items from GAAP to Non-GAAP
(Unaudited)
Dollars in thousands, except per share amounts

 

 

Three-months Ended

 

 

Nine-months Ended

 

Oct. 3,
2021

 

Jul. 4,
2021

 

Sept. 27,
2020

 

 

Oct. 3,
2021

 

Sept. 27,
2020

Discrete tax adjustments reconciliation

 

 

 

 

 

 

 

Income before income tax expense (GAAP)

$

88,584

 

 

$

93,538

 

 

$

101,309

 

 

 

$

260,953

 

 

$

121,991

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense (GAAP)

$

9,684

 

 

$

15,940

 

 

$

13,803

 

 

 

$

34,607

 

 

$

15,150

 

Effective tax rate (GAAP)

11

%

 

17

%

 

14

%

 

 

13

%

 

12

%

 

 

 

 

 

 

 

 

 

 

 

Discrete tax benefit related to stock-based compensation

3,250

 

 

1,431

 

 

4,354

 

 

 

9,888

 

 

10,447

 

Discrete tax benefit (expense) related to tax return filings and other

3,012

 

 

(535)

 

 

(129)

 

 

 

2,477

 

 

(3,638)

 

Total discrete tax adjustments

$

6,262

 

 

$

896

 

 

$

4,225

 

 

 

$

12,365

 

 

$

6,809

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense (Non-GAAP)

$

15,946

 

 

$

16,836

 

 

$

18,028

 

 

 

$

46,972

 

 

$

21,959

 

Effective tax rate (Non-GAAP)

18

%

 

18

%

 

18

%

 

 

18

%

 

18

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring and other charges and discrete tax adjustments reconciliation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (GAAP)

$

78,900

 

 

$

77,598

 

 

$

87,506

 

 

 

$

226,346

 

 

$

106,841

 

Excess and obsolete inventory charges

303

 

 

1,111

 

 

603

 

 

 

2,120

 

 

9,386

 

Restructuring charges

?

 

 

?

 

 

251

 

 

 

?

 

 

15,049

 

Intangible asset impairment charges

?

 

 

?

 

 

?

 

 

 

?

 

 

19,571

 

Tax effect on restructuring and other charges

(55)

 

 

(200)

 

 

(154)

 

 

 

(382)

 

 

(7,921)

 

Discrete tax adjustments

(6,262)

 

 

(896)

 

 

(4,225)

 

 

 

(12,365)

 

 

(6,809)

 

Net income (Non-GAAP)

$

72,886

 

 

$

77,613

 

 

$

83,981

 

 

 

$

215,719

 

 

$

136,117

 

Percentage of revenue (Non-GAAP)

26

%

 

29

%

 

33

%

 

 

27

%

 

23

%

 

 

 

 

 

 

 

 

 

 

 

Net income per diluted weighted-average common and common-equivalent share (GAAP)

$

0.44

 

 

$

0.43

 

 

$

0.49

 

 

 

$

1.26

 

 

$

0.61

 

Per share impact of non-GAAP adjustments identified above

(0.04)

 

 

?

 

 

(0.02)

 

 

 

(0.06)

 

 

0.16

 

Net income per diluted weighted-average common and common-equivalent share (Non-GAAP)

$

0.40

 

 

$

0.43

 

 

$

0.47

 

 

 

$

1.20

 

 

$

0.77

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted-average common and common-equivalent shares outstanding

180,342

 

 

179,991

 

 

177,138

 

 

 

180,109

 

 

176,038

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 3

COGNEX CORPORATION
Balance Sheets
(Unaudited)
Dollars in thousands

 

 

October 3, 2021

 

December 31, 2020

Assets

 

 

 

Cash and investments

$

985,386

 

 

$

767,438

 

Accounts receivable

129,784

 

 

125,696

 

Inventories

81,170

 

 

60,830

 

Property, plant, and equipment

76,882

 

 

79,173

 

Operating lease assets

24,154

 

 

22,582

 

Goodwill and intangible assets

254,581

 

 

259,633

 

Deferred tax assets

420,962

 

 

434,704

 

Other assets

75,884

 

 

50,646

 

 

 

 

 

Total assets

$

2,048,803

 

 

$

1,800,702

 

 

 

 

 

Liabilities and Shareholders' Equity

 

 

 

Accounts payable and accrued expenses

$

107,134

 

 

$

93,534

 

Deferred revenue and customer deposits

37,843

 

 

21,274

 

Operating lease liabilities

26,811

 

 

26,230

 

Income taxes

68,039

 

 

72,551

 

Deferred tax liabilities

302,019

 

 

314,952

 

Other liabilities

13,996

 

 

9,959

 

Shareholders' equity

1,492,961

 

 

1,262,202

 

 

 

 

 

Total liabilities and shareholders' equity

$

2,048,803

 

 

$

1,800,702

 

 


These press releases may also interest you

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
Discovery Silver Corp. ("Discovery" or the "Company") today announced financial results for the three and twelve months ended December 31, 2023 ("Q4 2023" and "2023", respectively). The Company also provided a summary of key events since the...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: